This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (30)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Venditti, L. N.
Right arrow Articles by Stanley, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Venditti, L. N.
Right arrow Articles by Stanley, C. A.
Related Collections
Right arrow Nutrition & Metabolism
PEDIATRICS Vol. 112 No. 5 November 2003, pp. 1005-1015

Newborn Screening by Tandem Mass Spectrometry for Medium-Chain Acyl-CoA Dehydrogenase Deficiency: A Cost-Effectiveness Analysis

Laura N. Venditti, MSc*, Charles P. Venditti, MD, PhD*,{ddagger}, Gerard T. Berry, MD{ddagger},||, Paige B. Kaplan, MD{ddagger}, Edward M. Kaye, MD{ddagger}, Henry Glick, PhD§ and Charles A. Stanley, MD||

* Department of Genetics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
{ddagger} Division of Human Genetics and Molecular Biology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
§ Department of General Internal Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
|| Division of Endocrinology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

Objective. To determine whether newborn screening by tandem mass spectrometry (MS/MS) for medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is cost-effective versus not screening and to define the contributions of disease, test, and population parameters on the decision.

Methods. A decision-analytic Markov model was designed to perform cost-effectiveness and cost-utility analyses measuring the discounted, incremental cost per life-year saved and per quality-adjusted life-year saved of newborn screening for MCADD compared with not screening. A hypothetical cohort of neonates made transitions among a set of health states that reflected clinical status, morbidity, and cost. Outcomes were estimated for time horizons of 20 and 70 years. Probabilities and costs were derived from a retrospective chart review of a 32-patient cohort treated over the past 30 years at the Children’s Hospital of Philadelphia, clinical experience with MCADD patient management, patient-family interviews, cost surveys, state sources, and published studies. In addition to older patients who came to medical attention by symptomatic presentation, our patient group included 6 individuals whose MCADD had been diagnosed by supplemental newborn screening. Estimates of the expected net changes in costs and life expectancy for MCADD screening were used to compute the incremental cost-effectiveness ratios. Sensitivity analyses were performed on key input variables, and 95% confidence intervals (CIs) were computed through second-order Monte Carlo simulations.

Results. In our base-case analysis over the first 20 years of life, the cost of newborn screening for MCADD was approximately $11 000 (2001 US dollars; 95% CI: <$0–$33 800) per life-year saved, or $5600 (95% CI: <$0–$17 100) per quality-adjusted life-year saved compared with not screening. Over a 70-year horizon, the respective ratios were approximately $300 (95% CI: <$0–$13 000) and $100 (95% CI: <$0–$6900). The results were robust when tested over plausible ranges for diagnostic test sensitivity and specificity, MCADD prevalence, asymptomatic rate, and screening cost.

Conclusions. Simulation modeling indicates that newborn screening for MCADD reduces morbidity and mortality at an incremental cost below the range for accepted health care interventions. At the 70-year horizon, the model predicts that almost all of the additional costs of screening would be offset by avoided sequelae.

Key Words: cost-utility • cost-effectiveness • newborn screening • inborn errors of metabolism • MCADD

Abbreviations: IEM, inborn error of metabolism • MS/MS, tandem mass spectrometry • MCADD, medium-chain acyl-CoA dehydrogenase deficiency • PKU, phenylketonuria • QALY, quality-adjusted life-year • USD, US dollars • CI, confidence interval

Received for publication Nov 14, 2002; Accepted Apr 2, 2003.




This article has been cited by other articles:


Home page
 Health Aff (Millwood)Home page
P. H. Arn
Newborn Screening: Current Status
Health Aff., March 1, 2007; 26(2): 559 - 566.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
S Sanderson, A Green, M A Preece, and H Burton
The incidence of inherited metabolic disorders in the West Midlands, UK
Arch. Dis. Child., November 1, 2006; 91(11): 896 - 899.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
M. Liebig, I. Schymik, M. Mueller, U. Wendel, E. Mayatepek, J. Ruiter, A. W. Strauss, R. J.A. Wanders, and U. Spiekerkoetter
Neonatal Screening for Very Long-Chain Acyl-CoA Dehydrogenase Deficiency: Enzymatic and Molecular Evaluation of Neonates With Elevated C14:1-Carnitine Levels
Pediatrics, September 1, 2006; 118(3): 1065 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
I. Griebsch, J. Coast, and J. Brown
Quality-Adjusted Life-Years Lack Quality in Pediatric Care: A Critical Review of Published Cost-Utility Studies in Child Health
Pediatrics, May 1, 2005; 115(5): e600 - e614.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
E. P. Diamandis
Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool: Opportunities and Potential Limitations
Mol. Cell. Proteomics, April 1, 2004; 3(4): 367 - 378.
[Abstract] [Full Text] [PDF]